Supply Chain
New research from Advisory Board, conducted in partnership with Staples Business, reveals how 102 health system supply chain and executive…
Prescriptions for Mylan's life-saving EpiPen medications have increased over the past four years, peaking every year in August. Last month, the number of prescriptions surpassed totals from the previous three Augusts, according to a report from athenahealth.
While Mylan CEO Heather Bresch has faced immense backlash for the rising cost of EpiPens and her correspondingly high salary, her father, Sen. Joe Manchin (D-W.Va.) is defending his daughter.
A Senate panel will look into Mylan's controversial price markups for the Amsterdam-based drugmakers life-saving EpiPen medication, reported NBC News.
The American Academy of Pediatrics has updated its annual flu season guidelines. The updates include a non-endorsement of AstraZeneca's nasal flu vaccine. The AAP asserts FluMist should not be used in any setting during the upcoming season.
Following the EpiPen price hike controversy, Allergan CEO Brent Saunders promises his company will limit price increases on its prescription drugs.
In response to increased scrutiny regarding the price of pharmaceuticals, the Biotechnology Innovation Organization launched a national ad campaign contending that expensive biotech drugs will reduce healthcare expenses in the long run by curing diseases, according to The Hill.
Carfentanil, the most potent commercial opioid in the world, is making its way into the U.S. drug supply, causing a string of accidental overdoses and deaths.
While a two-pack of EpiPens has a list price of $608, one industry expert estimates that Amsterdam-based Mylan spends no more than $20 to produce the product, according to NBC News.
Mylan CEO Heather Bresch continues to defend the high cost of EpiPens by pointing out that middlemen in the drug's supply chain take 55 percent of the medication's list price, according to Health Affairs.
An Atlanta AIDS group filed a federal complaint against Humana and Cigna, arguing that the insurance companies' high prices for HIV medications discriminate against those with the disease, according to The Atlanta Journal-Constitution.